Introduction: This study explores the therapeutic effects of the basal insulin analog Glargine on patients with poorly controlled type 2 diabetes mellitus (T2DM). The aim of the study was to evaluate the effects of Glargine on the body mass index (BMI), lipid profiles, and glycemic control in these patients. Glargine was given to a group of patients with poorly managed type 2 diabetes and they were observed for a predetermined amount of time. Method: This cohort study assessed the body mass index (BMI), lipid profile, and glycemic control in patients treated with Glargine. Results: Substantial drops in HbA1c levels were indicative of significant improvements in glycemic control. According to the findings, Patients' mean HbA1c decreased, indicating that Glargine was effective in reducing blood sugar levels and improving glycemic stability overall. In addition, the study found that lipid profiles had significantly improved. High-density lipoprotein (HDL) levels rose and total cholesterol and low-density lipoprotein (LDL) levels dropped considerably, indicating a positive effect on cardiovascular risk factors linked to diabetes. It's interesting to note that BMI changes were not significant, despite notable improvements in lipid profiles and glycemic control. This shows that the glycemic and lipid regulatory effects of glargine do not significantly affect body weight, which makes it a good choice for long-term T2DM management without the risk of weight gain, a common side effect of other insulin therapies. Conclusion: Glargine effectively manages glucose and lipid parameters without significantly impacting body weight. These findings underscore Glargine's potential as a beneficial treatment in managing poorly controlled T2DM.